Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.62 |
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3665721 | 0.87 | KCNH2 (0.61) | KCNH2HTR7ADRB1FFAR4 | |
| SCHEMBL20372819 | 0.82 | MAPT (0.51) | HTR7ADRB1ALDH1A1MAPT | |
| SCHEMBL13711972 | 0.81 | KCNH2 (0.84) | KCNH2HTR7ADRB1HRH1 | |
| SCHEMBL27366226 | 0.81 | ADRB1 (0.61) | KCNH2HTR7ADRB1FFAR4ALDH1A1 | |
| SCHEMBL27363469 | 0.80 | KCNH2 (0.49) | KCNH2HTR7ADRB1FFAR4MAPT | |
| SCHEMBL7924167 | 0.78 | KCNH2 (0.67) | KCNH2HTR7ADRB1ALDH1A1MAPT | |
| SCHEMBL10373770 | 0.78 | ADRB1 (0.74) | KCNH2HTR7ADRB1ALDH1A1MAPT | |
| SCHEMBL11103700 | 0.78 | ADRB1 (0.74) | KCNH2HTR7ADRB1ALDH1A1MAPT | |
| SCHEMBL4519876 | 0.77 | KCNH2 (1.00) | KCNH2HTR7 | |
| SCHEMBL14218788 | 0.77 | KCNH2 (0.77) | KCNH2HTR7ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024054591-A1 | RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |